Archive for Daily News

MDCO PDUFA date set. CYCC offering. BDSI initiates Phase 3 Clonidine Topical Gel trial.

Apr 04, 2014 No Comments by

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for […]

Daily News Read more

CPRX EXAS APPY announce offerings

Apr 03, 2014 No Comments by

Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced that it intends to offer shares of its common stock in a public offering. Exact Sciences Corp. (NASDAQ: EXAS) announced that it is offering $125 million of shares of its common stock in a proposed underwritten public offering. Venaxis, Inc. (NASDAQ: APPY) also announced that it intends to offer shares of its common stock […]

Daily News Read more

MNKD receives positive opinion from Adcom. ICPT offering + CPRX update.

Apr 02, 2014 No Comments by

MannKind Corporation (Nasdaq:MNKD) announced that the FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 1 to recommend that AFREZZA Inhalation Powder be granted approval by the FDA to improve glycemic control in adults with Type 1 diabetes. They also voted 14 to 0 in favour of adults with Type 2 diabetes. The PDUFA date is April […]

Daily News Read more

PRAN fails Phase 2 trial. DRTX postive Adcom vote. HRTX NDA filing due mid year + ANAC CRIS SYN updates

Apr 01, 2014 1 Comment

Prana Biotechnology (ASX:PBT/NASDAQ:PRAN) announced that they did not meet the primary endpoint in their Phase 2 trial of PBT2,  in Alzheimer’s Disease (IMAGINE Trial). Durata Therapeutics, Inc. (Nasdaq:DRTX) announced that the FDA Anti-Infective Drugs Advisory Committee voted 12 to 0 in favour of Dalvance (dalbavancin) for injection, for the treatment of adult patients with acute […]

Read more

EXAS receives positive Adcom vote. PSDV ALIM resubmit NDA. INSV NDA due 2H 2014 + updates for ARNA PTLA and CNAT

Mar 28, 2014 No Comments

pSivida Corp. (NASDAQ: PSDV) announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the FDA by Alimera Sciences (NASDAQ: ALIM). They noted they responded to questions raised in the October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe. Exact Sciences […]

Read more

AVNR PDUFA date set. INSM releases NTM data. MSTX initiates Phase 2 trial

Mar 26, 2014 No Comments

Insmed Incorporated (Nasdaq GS:INSM) announced that they did not meet the primary endpoint in their Phase 2 trial of ARIKAYCE, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections. The company noted that a key secondary endpoint, culture conversion, was met. Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced that the FDA has accepted their New […]

Read more

INSM data due today. CYCC topline Sapacitabine data due 2015. EXEL data due later this year + BIND EVOK ECYT news

Mar 26, 2014 No Comments

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) said it expects to complete enrolment in their Phase 3 SEAMLESS trial of Sapacitabine in patients with acute myeloid leukemia (AML). Topline data are due in 2015. Insmed Incorporated (NASDAQ: INSM) will announce results from its U.S. phase 2 clinical trial of ARIKAYCE, to treat nontuberculous mycobacteria (NTM) lung infections on Wednesday, March 26, 2014 at approximately 7:00 a.m. […]

Read more

QRXPY Adcom date set. RMTI submits NDA. ARIA and CYTR initiate pivotal trials.

Mar 25, 2014 No Comments

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced that the FDA has set 22 April 2014 as the date of the Advisory Committee meeting to consider the resubmitted Moxduo New Drug Application (NDA). The PDUFA date is 25 May, 2014. Rockwell Medical, Inc. (Nasdaq:RMTI)  announced the submission of a New Drug Application (NDA) to the FDA for Triferic (soluble […]

Read more

CPRX Phase 3 data due 3Q. Offerings for SGMO NBY + update for PTLA

Mar 20, 2014 No Comments

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that it has commenced a $100 million underwritten public offering of shares of its common stock. NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) announced that it intends to offer shares of its common stock and warrants in an underwritten public offering. Portola Pharmaceuticals (Nasdaq:PTLA) announced that it has initiated a Phase 3 […]

Read more

AERI Phase 2b data due early 3Q + updates for ADHD and IRWD.

Mar 19, 2014 No Comments

Alcobra Ltd. (Nasdaq:ADHD) announced that the first patient has been enrolled in a Phase 3 clinical trial of MDX in the treatment of Adults with ADHD. The trial is expected to be completed in 2H 2014. Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced that dosing has begun in its Phase 2a trial of IW-3718 in patients suffering from […]

Read more

NKTR Adcom date set. ICPT meets Phase 3 POISE endpoint + GWPH INO updates

Mar 18, 2014 No Comments

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced that it met the primary endpoint in its international Phase 3 POISE trial of obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC) demonstrated that OCA, at both a 10 mg dose and a 5 mg dose titrated to 10 mg. Nektar Therapeutic (NASDAQ: NKTR) and AstraZeneca have been […]

Read more